Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  sedoxantrone trihydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-8 of 8 for your search:
Start Over
Phase II Study of CI-958 for Metastatic or Locally Recurrent Colorectal Carcinoma (Summary last Modified 07/96)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: WSU-C-1287, NCI-T96-0003H, T96-0003
Phase II Study of CI-958 (a Benzothiopyranoindazole DNA Intercalator) for Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum (Summary Last Modified 06/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MDA-DM-96101, NCI-T96-0034D, T96-0034
Phase II Study of CI-958 for Refractory or Recurrent Ovarian Cancer (Summary Last Modified 05/98)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-8233, NCI-T96-0039H, T96-0039
Phase II Study of CI-958 in Hormone Refractory Metastatic Prostate Carcinoma (Summary Last Modified 10/1999)
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: OSU-9617, CWRU-1897, OSU-T96-0054, NCI-T96-0054D, T96-0054
Phase II Study of CI-958 in Recurrent Platinum-Sensitive Ovarian Cancer and Primary Peritoneal Carcinoma (Summary Last Modified 04/2002)
Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: GOG-146E
Phase II Open Label Study of CI-958 in Patients with Metastatic Breast Cancer (Summary Last Modified 01/98)
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: PD-958-05, NCI-V97-1208
Phase I Study of CI-958 (a Synthetic Intercalating Agent) for Recurrent Pediatric Solid Tumors and Lymphomas (Summary Last Modified 05/2000)
Phase: Phase I
Type: Treatment
Status: Completed
Age: 21 and under
Sponsor: NCI
Protocol IDs: CCG-0943
Start Over